Search

Pidolic acid

Pidolic acid is a naturally occurring but little-studied amino acid derivative that can be formed enzymatically or non-enzymatically and participates as a biological intermediate with unique pharmacodynamics … There are currently little to no medicines available that are clinically approved or marketed for employing pidolic acid as an active ingredient for any particular formal indication.

Carbopol 974P

The compound, known as BufferGel, was in advanced clinical trials for its ability to prevent pregnancy, but was discontinued. … It was under development by ReProtect LLC. It is a gel that may help both block the spread of sexually transmitted diseases and reduce unwanted pregnancies.

Zinc acetate

Levorphanol

It is nearly as effective orally as by injection.

Mebanazine

It was used in the past as an antidepressant in the 1960s, but has since been discontinued because of its hepatotoxic potential. … Mebanazine, also known as _Actomol_, is a monoamine oxidase inhibitor (MAOI) belonging to the _hydrazine_ class of chemicals.

Hydrocodone

[T116] It is commonly used in combination with [acetaminophen] to control moderate to severe pain. … Historically, hydrocodone has been used as a cough suppressant although this has largely been replaced by [dextromethorphan] in current cough and cold formulations.

Quizartinib

[A260641] Quizartinib was approved by the FDA in July 2023 and developed under the brand name VANFLYTA by Daiichi Sankyo. … [A260651] Therefore, quizartinib is proven to be a beneficial addition to the current AML treatment regimen, although serious side effects such as QT prolongation necessitates further research to optimize

Cefmenoxime

It is reported to exhibit high activity against a wide variety of gram-positive and gram-negative bacteria.

Icotrokinra

[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … It was jointly discovered and developed by Protagonist and Johnson & Johnson[L56118] and provides a novel, oral treatment option for patients requiring systemic therapy for plaque psoriasis.

Bimekizumab

of moderate-to-severe psoriasis,[A244450,A244455] likely owing to its dual inhibition of both IL-17A and IL-17F. … [L39665,L39680] It is the first IL-17 inhibitor to target both IL-17A and IL-17F.